MedTrace Logo

Safety and Efficacy of RHH646 for Knee Osteoarthritis

NCT05816395 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2026-03-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

RHH646

RHH646 capsule for oral use

DRUG

Placebo

RHH646 placebo capsule for oral use

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2025-02-24
Completion
2025-02-24
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Denmark
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05816395 on ClinicalTrials.gov